Evidence map›Paper›PMID 36820318›Full record

ArticleComputational and mathematical methods in medicine2023

Combined Network Pharmacology and Molecular Docking to Verify the Treatment of Type 2 Diabetes with

Jingxin Mao, Guowei Wang, Lin Yang, Lihong Tan, Cheng Tian, Lijing Tang, Ling Fang, Zhenqiang Mu, Zhaojing Zhu, Yan Li

Open access · hybridAbstract read
In one paragraph

Article in Computational and mathematical methods in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jingxin MaoChongqing Medical and Pharmaceutical College, Chongqing 400030, China.ORCID https://orcid.org/0000-0002-2813-1702
Guowei WangCollege of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.
Lin YangChongqing Medical and Pharmaceutical College, Chongqing 400030, China.
Lihong TanChongqing Medical and Pharmaceutical College, Chongqing 400030, China.
Cheng TianChongqing Medical and Pharmaceutical College, Chongqing 400030, China.
Lijing TangChongqing Medical and Pharmaceutical College, Chongqing 400030, China.
Ling FangChongqing Medical and Pharmaceutical College, Chongqing 400030, China.
Zhenqiang MuChongqing Medical and Pharmaceutical College, Chongqing 400030, China.
Zhaojing ZhuChongqing Medical and Pharmaceutical College, Chongqing 400030, China.ORCID https://orcid.org/0000-0002-8233-0489
Yan LiChongqing Medical and Pharmaceutical College, Chongqing 400030, China.ORCID https://orcid.org/0000-0001-5151-8318
Chongqing Medical and Pharmaceutical College · CNSouthwest University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To explore the potential molecular mechanism of Methods: The chemical constituents and core targets of RP and RS were searched by Traditional Chinese Medicine System Pharmacology (TCMSP); target genes related to T2DM were obtained through GeneCards database, component target network diagram was constructed, intersection genes of active compounds and T2DM were synthesized, protein-protein interaction (PPI) relationship was obtained, and core targets were screened by using Cytoscape 3.7.2. Gene Ontology (GO) biological process and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway were analyzed utilizing R studio 4.0.4 according to David database. Based on molecular docking, the screened active components of RP and RS were verified by molecular docking with the core target using Discovery Studio 2019. Results: There were totally 92 components and 29 corresponding targets in the component target network of RP and RS drug pair, of which 6 were the core targets of RP and RS in the treatment of T2DM. Molecular docking results showed that the active compounds of puerarin, formononetin, tanshinone iia, and luteolin had better binding activity with AKT1, VEGFA, NOS3, PPARG, MMP9, and VCAM1, respectively. Among them, puerarin showed significant effects in activating NOS3 pathway and luteolin exhibited significant effects in activating MMP9 pathway, respectively. The main biological processes mainly including xenobiotic stimulus, response to peptide, gland development, response to radiation, cellular response to chemical stress, response to oxygen levels, and the main signal pathways include response to xenobiotic stimulus, cellular response to chemical stress, response to peptide, gland development, and response to oxygen levels. Conclusion: Network pharmacology is an effective tool to explain the action mechanism of Traditional Chinese Medicine (TCM) from the overall perspective. RP and RS pair could alleviate T2DM via the molecular mechanism predicted by the network pharmacology, which provided new ideas and further research on the molecular mechanism of T2DM.

Indexed as

Diabetes Mellitus, Type 2Drugs, Chinese HerbalPuerariaHumansLuteolinMatrix Metalloproteinase 9Medicine, Chinese TraditionalMolecular Docking SimulationNetwork PharmacologySalviaXenobioticsDrugs, Chinese HerbalLuteolinMatrix Metalloproteinase 9Xenobiotics

Identifiers

PMID36820318
PMCPMC9938769
OpenAlexW4320035743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.